Network pharmacology analysis and bioinformatics analysis showed that PTGS2, JUN, MYC, and CDKN1A might be crucial target genes in the primary mechanism of SQP in treating NASH and improving the inflammatory response. This evidence concerns the gene PTGS2 and metabolic dysfunction-associated steatohepatitis.